

JFW

Attorney Docket No. VPI/01-09 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/775,687
Confirmation No.: 9163
Filing Date: February 10, 2004
Examiner: Ba K. Trinh
Group Art Unit: 1625
Applicants: John R. Snoonian et al.
For: PROCESSES FOR THE FACILE SYNTHESIS OF DIARYL AMINES
AND ANALOGUES THEREOF

August 9, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copy(ies) of references Citation No(s). **B1, C1-C5** is/are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- ☒ A copy of the International Search Report received in the corresponding PCT Application No. **PCT/US2004/003933** is attached herewith.

- (b) ☐ No fee is believed due because:


- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

Applicants: Snoonian et al.
Application No.: 10/775,687

- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.


Applicants: Snoonian et al.
Application No.: 10/775,687


Respectfully submitted,



Karen E. Brown
Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited
with the U.S. Postal Service as First Class Mail in an envelope
addressed to Commissioner for Patents, Mail Stop: Amendment,
P.O. Box 1450, Alexandria, VA 22313-1450 on August 9, 2005.




Date of Signature



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/775,687
	Filing Date	February 10, 2004
	First Named Inventor	John R. Snoonian
	Group Art Unit	1625
	Examiner Name	Ba K. Trinh
	Attorney Docket Number	VPI/01-09 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	02/14281 A1	Cochran et al.	21 February 2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Cao, Jianjing et al., "[3- <i>cis</i> -3,5-dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter," Bioorg. & Med. Chem. Lett. 11:3169-73 (2001)
	C2	Sucholeiki, Irving et al., "New polyoxyalkyleneamine-grafted paramagnetic supports for solid-phase synthesis and bioapplications," Tetrahedron Lett. 42: 3279-82 (2001)
	C3	Beilstein Database Accession No. BEILSTEIN REACTION ID 4342815
	C4	Seto, Christopher T. et al., "Molecular self-assembly through hydrogen bonding: Aggregation of five molecules to form a discrete supramolecular structure," J. Am. Chem. Soc. 113: 1321-29 (1993)
	C5	Rewcastle, Gordon W. et al., "Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia," J. Med. Chem. 30:1576-81 (1987)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Our Docket No.: VPI/01-09 US



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Director of U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

On August 9, 2005
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (B1, C1-C5); and
4. Return Postcard.

Susan Batty-Gunn
Signature

Susan Batty-Gunn
Typed or printed name of person signing Certificate